Discover
RLMD
Relmada Therapeutics, Inc.
6.39
2 x 4.95
2 x 8.15
bid
ask
-
0.53
7.66%
2 @ 05:24 AM
6.35 -0.04 (0.63%)
| Ytd | 32.30% | |
| 1y | 963.23% |
6.30
day range
6.97
0.55
52 week range
8.00
| Open | 6.88 | Prev Close | 6.92 | Low | 6.30 | High | 6.97 | Mkt Cap | 670.87M |
| Vol | 1.87M | Avg Vol | 1.58M | EPS | -1.09 | P/E | N/A | Forward P/E | -0.19 |
| Beta | 0.41 | Short Ratio | 4.52 | Inst. Own | 46.06% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 6.93 | 200-d Avg | 4.81 | 1yr Est | 0.87 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.65 | -0.72 | -0.07 | -10.77% |
| 2024-08-07 | 2024-06 | -0.83 | -0.59 | 0.24 | 28.92% |
| 2024-05-08 | 2024-03 | -0.9 | -0.72 | 0.18 | 20.00% |
| 2024-03-19 | 2023-12 | -0.88 | -0.84 | 0.04 | 4.55% |
| 2023-11-08 | 2023-09 | -0.95 | -0.73 | 0.22 | 23.16% |
| 2023-08-08 | 2023-06 | -0.92 | -0.84 | 0.08 | 8.70% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-05 | Mizuho | Downgrade | Outperform | Neutral |
| 2024-12-04 | Leerink Partners | Downgrade | Outperform | Market Perform |
| 2024-06-05 | Goldman Sachs | Downgrade | Neutral | Sell |
| 2023-06-15 | Mizuho | Upgrade | Buy | Buy |
| 2023-01-23 | SVB Leerink | Upgrade | Outperform | |
| 2022-10-14 | Goldman Sachs | Downgrade | Buy | Neutral |
Profile
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-21 | CASAMENTO CHARLES J | Director | 0.00 | Stock Gift |
| 2024-01-30 | ENCE CHARLES | Officer | 38.97K | Purchase |
| 2024-09-08 | KELLY PAUL EDWARD | Director | 212.30K | Purchase |
| 2023-05-22 | O'GORMAN CEDRIC | Officer | 10.12K | Purchase |
| 2024-09-10 | SHENOUDA MAGED R | Chief Financial Officer | 88.34K | Purchase |
| 2024-09-10 | TRAVERSA SERGIO | Chief Executive Officer | 384.02K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Franklin Resources, Inc. | 1.30M | 494.30K | 13.16% |
| 2024-09-29 | Vanguard Group Inc | 1.26M | 477.05K | 12.70% |
| 2024-09-29 | Acadian Asset Management. LLC | 1.19M | 450.38K | 11.99% |
| 2024-09-29 | Parsons Capital Management, Inc. | 1.00M | 380.62K | 10.13% |
| 2024-09-29 | Palo Alto Investors Lp | 732.40K | 278.02K | 7.40% |
| 2024-09-29 | Deep Track Capital, Lp | 674.83K | 256.17K | 6.82% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 851.92K | 323.39K | 8.61% |
| 2024-07-30 | Franklin Strategic Series-Franklin Biotechnology Discove | 374.03K | 141.98K | 3.78% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 353.63K | 134.24K | 3.57% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 157.02K | 59.61K | 1.59% |
| 2024-09-29 | Bridgeway Funds Inc-Ultra Small Company Fund | 100.18K | 38.03K | 1.01% |
| 2024-10-30 | AdvisorShares Trust-AdvisorShares Psychedelics ETF | 93.08K | 35.33K | 0.94% |
Split
| Split | Date |
|---|---|
| 1 : 4 | 2019-09-30 |
| 1 : 5 | 2015-08-12 |